Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Bioatla.
NAMPT neuroprotection Chris Cain doi:10.1038/scibx.2014.1112 Google-backed antiaging play Calico has filled its first pipeline program by in-licensing analogs of P7C3 after new research showed that the molecules block neurodegeneration by inhibiting NAMPT. Full Text | PDF
A conversation with Jeffrey Settleman Kai-Jye Lou doi:10.1038/scibx.2014.1113 SciBX spoke with Genentech's Jeffrey Settleman about resistance mechanisms against kinase inhibitors used to treat cancer and what should be done to tackle the problem. Full Text | PDF
Progressive thinking in MS C. Simone Fishburn doi:10.1038/scibx.2014.1114 The International Progressive MS Alliance is pushing for advances in progressive MS—an understudied form of the disease—by funding 22 projects in the pilot phase of its 5-year, €22 million ($28 million) initiative. Full Text | PDF
A CRISPR possibility for DMD Lauren Martz doi:10.1038/scibx.2014.1115 Findings that CRISPR-based genome editing can improve symptoms in a mouse model of Duchenne muscular dystrophy could lead to a therapeutic use of the technology, whose impact has thus far been as a research tool. Full Text | PDF
IgA doi:10.1038/scibx.2014.1116 Studies in patient samples and mice suggest depleting IgA-coated microbiota could help treat IBD. Full Text | PDF
v-Rel reticuloendotheliosis viral oncogene homolog A (RELA; p65) doi:10.1038/scibx.2014.1117 Mouse studies suggest peptide-siRNA nanocomplexes targeting p65 could help treat RA and other inflammatory diseases. Full Text | PDF
Ceramide kinase (CERK) doi:10.1038/scibx.2014.1118 Mouse studies suggest CERK inhibition could help suppress recurrent breast cancer. Full Text | PDF
Insulin-like growth factor-1 receptor (IGF1R; CD221); dishevelled segment polarity protein 3 (DVL3) doi:10.1038/scibx.2014.1119 Studies in vitro and in human samples suggest IGF1R inhibitors could be most effective in patients with cancer who show suppressed DVL3 expression. Full Text | PDF
RAF/MEK/ERK pathway; protein kinase Cη (PRKCH) doi:10.1038/scibx.2014.1120 Mouse and cell culture studies suggest inhibiting PRKCH or the RAF/MEK/ERK pathway could help treat CML resistant to Gleevec imatinib. Full Text | PDF
Anaplastic lymphoma kinase (ALK); insulin-like growth factor-1 receptor (IGF1R; CD221) doi:10.1038/scibx.2014.1121 Studies in patient-derived cell lines and mice, based on a patient case study, suggest combined inhibition of ALK and IGF1R could be useful for treating ALK+ lung cancers resistant to Xalkori crizotinib. Full Text | PDF
Eukaryotic translation initiation factor 4F (eIF4F) doi:10.1038/scibx.2014.1122 Cell culture studies suggest inhibiting eIF4F activity could help improve the efficacy of dexamethasone therapy in MM. Full Text | PDF
Wolf-Hirschhorn syndrome candidate 1 (WHSC1; MMSET; NSD2) doi:10.1038/scibx.2014.1123 Mouse studies suggest inhibiting MMSET could help treat certain forms of MM. Full Text | PDF
HIV env doi:10.1038/scibx.2014.1124 Nonhuman primate studies suggest optimized broadly neutralizing antibodies (bNAbs) against the HIV env protein could help prevent HIV infection. Full Text | PDF
HIV env; Fc γ-receptor (FCGR) doi:10.1038/scibx.2014.1125 Mouse studies suggest strengthening the affinity of broadly neutralizing antibodies (bNAbs) for activating FCGRs could enhance their therapeutic effect against HIV infection. Full Text | PDF
Sortase (srtA) doi:10.1038/scibx.2014.1126 In vitro and mouse studies suggest Staphylococcus aureus srtA inhibitors could help prevent hospital-acquired S. aureus infection. Full Text | PDF
Marburg virus nucleoprotein doi:10.1038/scibx.2014.1127 Nonhuman primate studies suggest lipid nanoparticle–encapsulated siRNA targeting a conserved sequence region of Marburg virus nucleoprotein could be used to treat Marburg virus infection. Full Text | PDF
β-amyloid (Aβ); β-site APP-cleaving enzyme 1 (BACE1) doi:10.1038/scibx.2014.1128 Mouse studies suggest combining an anti-Aβ antibody with a BACE1 inhibitor could help treat AD. Full Text | PDF
NF-κB; tumor necrosis factor-α (TNF-α); ubiquitin-conjugating enzyme E2D 1 (UBE2D1; UbcH5) doi:10.1038/scibx.2014.1129 Mouse and in vitro studies have identified a sesquiterpene lactone derived from the Inula japonica Thunb herb that could help treat autoimmune and inflammatory diseases. Full Text | PDF
Aqueous multiphase systems to test for sickle cell disease (SCD) doi:10.1038/scibx.2014.1130 Aqueous multiphase systems could be used to test patients for SCD in resource-limited settings in a rapid and cost-effective manner. Full Text | PDF
Reprogramming specificity of sortase enzymes doi:10.1038/scibx.2014.1131 A method to reprogram the substrate preference of sortase enzymes could help generate variants of the enzyme that can aid protein conjugation. Full Text | PDF
Stabilized drug linker for antibody-drug conjugates (ADCs) doi:10.1038/scibx.2014.1132 In vitro and rodent studies suggest a stabilized drug linker in ADCs could result in improved antitumor activity. Full Text | PDF
Synthetic fermentation of bioactive β-peptide–based α-ketoamides doi:10.1038/scibx.2014.1133 In vitro studies suggest synthetic fermentation of bioactive β-peptide–based α-ketoamides can be used to prepare thousands of unnatural peptides that can be screened for biological activity. Full Text | PDF
Unadapted, pathogenic simian/human immunodeficiency viruses (SHIVs) to model AIDS doi:10.1038/scibx.2014.1134 Nonhuman primate studies suggest that newly generated mucosally transmittable SHIV strains could help model AIDS and screen for prophylactic interventions. Full Text | PDF
Cyclodextrin-polymer nanoparticle delivery of combination siRNA payloads doi:10.1038/scibx.2014.1135 In vitro and mouse studies suggest cyclodextrin-polymer nanoparticle delivery of combination siRNA payloads could help treat K-Ras (KRAS)-mutant cancers. Full Text | PDF
Analyzing biosynthetic gene clusters of the human microbiome to identify antibiotics doi:10.1038/scibx.2014.1136 Systematic analysis of biosynthetic gene clusters from the human microbiome could be useful for identifying new antibiotics. Full Text | PDF
Structure-guided design of concentrative nucleoside transporter (CNT)-mediated therapies doi:10.1038/scibx.2014.1137 Structural data on CNTs could guide the design of new drugs that exploit the transporter to enter cells. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment